Sign In
Buy VERX
$12.98
+0.600 (+4.85%)
At Close: Jul 13, 2026
Alpine Immune Sciences soars on $4.9bn Vertex takeover
07:16am, Thursday, 11'th Apr 2024
Alpine Immune Sciences Inc shares continued higher in pre-market trading, after soaring on Wednesday following news of the firm's US$4.9 billion takeover by Vertex Pharmaceuticals Incorporated. Shares
Vertex Stock in Focus After Deal to Buy Alpine Immune For $4.9B—Key Level to Watch
10:45pm, Wednesday, 10'th Apr 2024
Vertex Pharmaceuticals (VRTX) will acquire clinical-stage immunotherapy company Alpine Immune Sciences (ALPN) in a deal valued at around $4.9 billion, both companies said Wednesday.
Vertex will buy Alpine Immune Sciences for $4.9B in another big Seattle biotech deal
08:16pm, Wednesday, 10'th Apr 2024
Boston-based biotech company Vertex Pharmaceuticals agreed to acquire Seattle-based Alpine Immune Sciences for $65 per share, totaling about $4.
Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion
05:15pm, Wednesday, 10'th Apr 2024
Vertex Pharmaceuticals has agreed to acquire Alpine Immune Sciences for $4.9 billion in cash, bolstering its portfolio on kidney diseases as deals in biotechnology continue to heat up.
Vertex Pharmaceuticals Nabs Alpine Immune Sciences In $4.9 Billion Deal
04:45pm, Wednesday, 10'th Apr 2024
Vertex Pharmaceuticals will pay $4.9 billion to acquire Alpine Immune Sciences. Alpine stock rocketed.
Vertex Pharmaceuticals to buy Alpine Immune Sciences for $4.9 bln
04:20pm, Wednesday, 10'th Apr 2024
Vertex Pharmaceuticals will acquire therapy developer Alpine Immune Sciences for $65 per share, or about $4.9 billion in cash, the companies said on Wednesday.
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
04:01pm, Wednesday, 10'th Apr 2024
BOSTON & SEATTLE--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a biotechnology company focused on discovering and developing inn
Vertex: A Positive Growth Outlook With Margins At An Inflection Point
10:47pm, Wednesday, 20'th Mar 2024
Vertex is recommended as a buy due to positive growth metrics and strong cross-selling abilities. Recent results show revenue and adjusted EBITDA beating expectations, with strong annual recurring rev
Vertex: EPS Better Than Expected, Cloud Offerings, And Cheap
07:39am, Tuesday, 19'th Mar 2024
Vertex, Inc. delivered better-than-expected EPS and net sales growth, leading to optimism in the market. The company operates in a large market with significant geographic diversification and a large
Earnings Estimates Moving Higher for Vertex (VERX): Time to Buy?
01:20pm, Thursday, 07'th Mar 2024
Vertex (VERX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Does Vertex (VERX) Have the Potential to Rally 25.21% as Wall Street Analysts Expect?
10:56am, Thursday, 07'th Mar 2024
The consensus price target hints at a 25.2% upside potential for Vertex (VERX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate r
Vertex (VERX) Tops Q4 Earnings and Revenue Estimates
09:26am, Thursday, 29'th Feb 2024
Vertex (VERX) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.08 per share a year ago.
Vertex to Announce Fourth Quarter 2023 Financial Results on Thursday, February 29, 2023
05:28pm, Thursday, 01'st Feb 2024
KING OF PRUSSIA, Pa., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX), a leading global technology provider of indirect tax solutions, today announced that it will release fourth quarter
Call of the Day: Vertex
01:28pm, Thursday, 28'th Dec 2023
Jim Lebenthal, chief equity strategist at Cerity Partners, and Bryn Talkington, managing partner at Requisite Capital Management, join CNBC's 'Halftime Report' to debate the biotech names to own and m
Vertex: Growth Momentum Can Continue In The Near Term
05:02am, Thursday, 14'th Dec 2023
Reiterate the buy rating for VERX as it has strong growth momentum and pricing growth in FY24. Recent results show revenue growth, improved margins, and strong operating metrics. Vertex is well-positi
